# UNITE Study: Understanding New Interventions With GBM ThErapy

> **NCT03419403** · PHASE3 · TERMINATED · sponsor: **AbbVie** · enrollment: 40 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** Steroid eye drops
- **DRUG:** Vasoconstrictor eye drops
- **OTHER:** Cold compress
- **DRUG:** Ophthalmic steroid ointment
- **DRUG:** Depatuxizumab mafodotin
- **DRUG:** Temozolomide
- **RADIATION:** Radiation

## Key facts

- **NCT ID:** NCT03419403
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-30
- **Primary completion:** 2019-09-05
- **Final completion:** 2020-03-03
- **Target enrollment:** 40 (ACTUAL)
- **Why stopped:** The study was terminated because clinical development of depatuxizumab mafodotin in glioblastoma was stopped due to lack of survival benefit.
- **Last updated:** 2021-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03419403

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03419403, "UNITE Study: Understanding New Interventions With GBM ThErapy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03419403. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*